As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.
| Mar '25 | 
         
    +/-
   
  
    %
   
 | 
      ||
| Revenue | - - | 
         
    -
 
        
       | 
      |
| Gross Profit | - - | 
         
    -
 
        
       | 
      |
| EBITDA | -19 -19 | 
         
      
        
        20%
      
      
        
        20%
      
 
        
       | 
      |
| EBIT (Operating Income) EBIT | -19 -19 | 
         
      
        
        19%
      
      
        
        19%
      
 
        
       | 
      |
| Net Profit | -67 -67 | 
         
      
        
        23%
      
      
        
        23%
      
 
        
       | 
      |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.
| Head office | United States | 
| CEO | David Weinstein | 
| Employees | 25 | 
| Founded | 2011 | 
| Website | renovarobio.com | 
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


